Ann Liebeskind, Don P Wilson
No abstract text is available yet for this article.
September 27, 2023: Journal of Clinical Lipidology
Janneke W C M Mulder, Annette M H Galema-Boers, Jeanine E Roeters van Lennep
BACKGROUND AND OBJECTIVE: Inclisiran is the first-in-class small interfering RNA (siRNA) PCSK9 inhibitor. In clinical trials inclisiran showed effective and sustained LDL-C reduction of ± 50 %. As data in clinical setting are scarce, we aim to investigate the efficacy and safety in clinical practice. METHODS: We describe a registry of consecutive patients who started with inclisiran at a lipid clinic of a university hospital. Patients were eligible if they fulfilled the reimbursement criteria in the Netherlands...
September 18, 2023: Journal of Clinical Lipidology
Manabu Takahashi, Hiroaki Okazaki, Hayato Tada, Shun Ishibashi
Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by mutations in the sterol 27-hydroxylase gene (CYP27A1). Due to the deficiency of 27-hydroxylase, the synthesis of bile acids from cholesterol is impaired and excessive cholestanol accumulates in various tissues, such as the central nervous system, tendons, and lenses. Patients with CTX typically manifest intellectual decline, pyramidal tract symptoms, cerebellar symptoms, tendon xanthomas, juvenile cataracts, neonatal jaundice, chronic diarrhea, osteoporosis, and premature cardiovascular disease...
September 17, 2023: Journal of Clinical Lipidology
Md Tauhidul Islam, Md Taqbir Us Samad Talha, Sabit Saad Shafiq, Tapas Mazumder, Rajat Das Gupta, Md Shahjahan Siraj
BACKGROUND: The burden of dyslipidemia in Bangladesh remains inadequately characterized. OBJECTIVES: To determine and describe the prevalence and pattern of dyslipidemia and its associated risk factors among an adult Bangladeshi population. DESIGN: Population-based, cross-sectional study. Participants were adults living in all eight administrative divisions of Bangladesh. The total sample size was 7084 (53.1 % women, 46.9% urban residents)...
September 15, 2023: Journal of Clinical Lipidology
Emilio Ortega, Bogdan Vlacho, Ray Puig Treserres, Manel Mata-Cases, Andreu Altes, Dídac Mauricio, Josep Franch-Nadal
BACKGROUND: Hypertriglyceridemia (HTG) increases the risk of cardiovascular disease and pancreatitis, and its prevalence varies across populations. OBJECTIVE: To determine the prevalence of moderate-to-severe hypertriglyceridemia (msHTG, 500-879 mg/dl) and severe hypertriglyceridemia (sHTG, ≥ 880 mg/dl) in a primary care population in Catalonia, Spain, and to categorize them according to presence/absence of factors potentially causing HTG. METHODS: Retrospective analysis of clinical and laboratory data in SIDIAP (Information System for the Development of Primary Care Research) from 2010, 2013, 2016, and 2019...
September 9, 2023: Journal of Clinical Lipidology
Jing Guo, Yuan Peng, Ruihua Liu, Chunyan Yi, Qunying Guo, Xiao Yang
BACKGROUND: Patients undergoing peritoneal dialysis (PD) are prone to dyslipidemia. However, studies concerning remnant cholesterol (RC) in such patients are limited. OBJECTIVE: We aimed to investigate the association between RC and cardiovascular (CV) mortality in patients on PD. METHODS: Patients who initiated PD at our center (2006-2018) were retrospectively enrolled. Adjusted Cox models were used to evaluate the independent association between baseline RC levels and CV mortality...
September 9, 2023: Journal of Clinical Lipidology
Thea Bismo Strøm, Emil Asprusten, Jon K Laerdahl, Irene Øygard, M Mahmood Hussain, Martin Prøven Bogsrud, Trond P Leren
BACKGROUND: Molecular genetic testing of patients with hypobetalipoproteinemia may identify a genetic cause that can form the basis for starting proper therapy. Identifying a genetic cause may also provide novel data on the structure-function relationship of the mutant protein. OBJECTIVE: To identify a genetic cause of hypobetalipoproteinemia in a patient with levels of low density lipoprotein cholesterol at the detection limit of 0.1 mmol/l. METHODS: DNA sequencing of the translated exons with flanking intron sequences of the genes adenosine triphosphate-binding cassette transporter 1, angiopoietin-like protein 3, apolipoprotein B, apolipoprotein A1, lecithin-cholesterol acyltransferase, microsomal triglyceride transfer protein and proprotein convertase subtilisin/kexin type 9...
September 9, 2023: Journal of Clinical Lipidology
Akihiro Nomura, Hirofumi Okada, Atsushi Nohara, Masa-Aki Kawashiri, Masayuki Takamura, Hayato Tada
BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal dominant monogenic disease characterized by high low-density lipoprotein cholesterol (LDL-C) levels. Although carrying causative FH variants is associated with coronary heart disease (CHD), it remains unclear whether disclosing its associated cardiovascular risk affects outcomes in patients with FH. OBJECTIVE: We aimed to evaluate the efficacy of providing future cardiovascular risk based on genetic testing in addition to a standard FH education program...
August 26, 2023: Journal of Clinical Lipidology
Alberto Cordero, Rosa Fernández Olmo, Lina Badimon, Carlos G Santos-Gallego, José M Castellano, Lorenzo Fácila, Moisés Rodriguez-Manero, Clara Bonanad, Gemma Vilahur, David Escribano, Juan J Badimon, José R González-Juanatey
BACKGROUND: Statins are the cornerstone of lipid-lowering therapy (LLT) for reduction of low-density lipoprotein cholesterol (LDLc) levels and high percentage of patients require LLT combinations or alternative treatments for adequate LDLc control. METHODS: We performed an intention-to-treat metanalysis of published data of phase III trials evaluating LLT efficacy on major adverse cardiovascular events (MACE). The primary endpoint was MACE incidence, as reported in each trial, and secondary analyses included myocardial infarction, stroke and mortality...
August 22, 2023: Journal of Clinical Lipidology
Sarah E Eppley, Rona Z Silkiss
This report describes an unusual and diagnostically challenging case of subcutaneous soft tissue xanthogranulomas of bilateral orbits of a 58-year-old female patient seen in a private oculoplastics practice. Accurate and timely diagnosis is crucial in xanthogranulomatous diseases so that any systemic manifestations can be identified and addressed in a multidisciplinary fashion. Periorbital xanthogranuloma is a frequent early manifestation of adult xanthogranulomatous disease, and its association with life-threatening systemic disease requires accurate diagnosis and prompt work-up...
August 16, 2023: Journal of Clinical Lipidology
Alexander R Zheutlin, Joshua A Jacobs, Catherine G Derington, Alexander Chaitoff, Ann Marie Navar, Adam P Bress
Statin use among younger adults at high atherosclerotic cardiovascular disease (ASCVD) risk compared with older adults at the same risk is unclear. We determined prevalent statin use by 10-year ASCVD risk and age among US participants aged 40-75 eligible for risk-indicated primary prevention statins from the 2013-2020 National Health and Nutrition Examination Survey cycles. Among 3,503 participants, statin use by ASCVD risk (5-<7.5%, 7.5-<20%, and ≥20%) was 9.4%, 9.0%, and 12.2% among those age 40-54 compared to 22...
August 12, 2023: Journal of Clinical Lipidology
Natalie C Ward, Qidi Ying, Dick C Chan, Jing Pang, Trevor A Mori, Carl J Schultz, Girish Dwivedi, Roslyn J Francis, Gerald F Watts
Elevated lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease. However, there are no approved and effective treatments for lowering Lp(a) and the associated cardiovascular risks. Omega-3 fatty acids (ω-3FAs), primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have both triglyceride-lowering and anti-inflammatory properties. This pilot study investigated the effect of high dose ω-3FAs (3.6 g/day) on arterial inflammation in 12 patients with elevated Lp(a) (> 0...
August 12, 2023: Journal of Clinical Lipidology
Joon-Tae Kim, Ji Sung Lee, Beom Joon Kim, Jihoon Kang, Keon-Joo Lee, Jong-Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Tai Hwan Park, Kyungbok Lee, Jun Lee, Keun-Sik Hong, Yong-Jin Cho, Hong-Kyun Park, Byung-Chul Lee, Kyung-Ho Yu, Mi Sun Oh, Dong-Eog Kim, Wi-Sun Ryu, Jay Chol Choi, Jee-Hyun Kwon, Wook-Joo Kim, Dong-Ick Shin, Kyu Sun Yum, Sung Il Sohn, Jeong-Ho Hong, Sang-Hwa Lee, Man-Seok Park, Kang-Ho Choi, Juneyoung Lee, Kwang-Yeol Park, Hee-Joon Bae
BACKGROUND: Lipid paradox of low LDL-C may cause physicians to be reluctant to use statins in acute ischemic stroke (AIS) patients with low LDL-C levels at admission. OBJECTIVE: This study investigated the association between LDL-C levels and early vascular outcomes and assessed the potential interaction effect between LDL-C and statin pretreatment on early outcomes. PATIENTS AND METHODS: This was a study of a prospective, multicenter, registry of AIS patients with admission LDL-C...
August 8, 2023: Journal of Clinical Lipidology
Shehan D Perera, Jian Wang, Adam D McIntyre, Robert A Hegele
BACKGROUND: Biallelic pathogenic variants in APOA5 are an infrequent cause of familial chylomicronemia syndrome characterized by severe, refractory hypertriglyceridemia (HTG), and fasting plasma triglyceride (TG) >10 mmol/L (>875 mg/dL). The TG phenotype of heterozygous individuals with one copy of a pathogenic APOA5 variant is less familiar. We evaluated the longitudinal TG phenotype of individuals with a single pathogenic APOA5 variant allele. METHODS: Medically stable outpatients from Ontario, Canada were selected for study based on having: 1) a rare pathogenic APOA5 variant in a single allele; and 2) at least three serial fasting TG measurements obtained over >1...
August 7, 2023: Journal of Clinical Lipidology
Katarina Clegg, Tyler J Schubert, Robert C Block, Frances Burke, Nihar R Desai, Robert Greenfield, Dean Karalis, Penny M Kris-Etherton, Catherine J McNeal, Rachel Nahrwold, Jessica M Peña, Roda Plakogiannis, Nathan D Wong, Laney K Jones
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in the United States. Case-based learning using electronic delivery of the modules can educate clinicians and improve translation of evidence-based guidelines into practice for high-risk ASCVD patients. OBJECTIVE: To develop and optimize module design, content, and usability of e-learning modules to teach clinicians evidence-based management in accordance with multi-society guidelines for high-risk ASCVD patients that will be implemented and evaluated in U...
August 2, 2023: Journal of Clinical Lipidology
Carmen E Annevelink, Philip A Sapp, Kristina S Petersen, Greg C Shearer, Penny M Kris-Etherton
Palmitic acid is the predominant dietary saturated fatty acid (SFA) in the US diet. Plasma palmitic acid is derived from dietary fat and also endogenously from de novo lipogenesis (DNL) and lipolysis. DNL is affected by excess energy intake resulting in overweight and obesity, and the macronutrient profile of the diet. A low-fat diet (higher carbohydrate and/or protein) promotes palmitic acid synthesis in adipocytes and the liver. A high-fat diet is another source of palmitic acid that is taken up by adipose tissue, liver, heart and skeletal muscle via lipolytic mechanisms...
July 28, 2023: Journal of Clinical Lipidology
Maryam Darabi, Marie Lhomme, Maharajah Ponnaiah, Maja Pučić-Baković, Isabelle Guillas, Eric Frisdal, Randa Bittar, Mikaël Croyal, Lucrèce Matheron-Duriez, Lucie Poupel, Dominique Bonnefont-Rousselot, Corinne Frere, Mathilde Varret, Michel Krempf, Bertrand Cariou, Gordan Lauc, Maryse Guerin, Alain Carrie, Eric Bruckert, Philippe Giral, Wilfried Le Goff, Anatol Kontush
BACKGROUND: The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in dyslipidemia may go beyond its immediate effects on low-density lipoprotein receptor (LDL-R) activity. OBJECTIVE: This study aimed to assess PCSK9-derived alterations of high-density lipoprotein (HDL) physiology, which bear a potential to contribute to cardiovascular risk profile. METHODS: HDL was isolated from 33 patients with familial autosomal dominant hypercholesterolemia (FH), including those carrying PCSK9 gain-of-function (GOF) genetic variants (FH-PCSK9, n = 11), together with two groups of dyslipidemic patients employed as controls and carrying genetic variants in the LDL-R not treated (ntFH-LDLR, n = 11) and treated (tFH-LDLR, n = 11) with statins, and 11 normolipidemic controls...
July 27, 2023: Journal of Clinical Lipidology
Britt E Heidemann, A David Marais, Monique T Mulder, Frank L J Visseren, Jeanine E Roeters van Lennep, Erik S G Stroes, Niels P Riksen, Leonie C van Vark-van der Zee, Dee M Blackhurst, Charlotte Koopal
BACKGROUND: PCSK9 monoclonal antibodies (mAbs) reduce fasting and post fat load cholesterol in non-HDL and IDL in familial dysbetalipoproteinemia (FD). However, the effect of PCSK9 mAbs on the distribution and composition of atherogenic lipoproteins in patients with FD is unknown. OBJECTIVE: To evaluate the effect of the PCSK9 mAb evolocumab added to standard lipid-lowering therapy in patients with FD on fasting and post fat load lipoprotein distribution and composition...
July 22, 2023: Journal of Clinical Lipidology
P Barton Duell, Rana Dutta, Ashley Wolf, Hollisa Rosengrant
Cerebrotendinous xanthomatosis (CTX) is a rare, autosomal recessive disorder of bile acid synthesis that presents with varied and progressive symptomology. Early treatment with chenodeoxycholic acid (CDCA) improves symptoms and slows degeneration. Patients with CTX are commonly recommended to discontinue CDCA treatment during pregnancy because of theoretical risks to the fetus, but patient and clinician concerns about the risks of stopping treatment cause uncertainty. Herein, we report the experiences and perspectives of two women with CTX from the time of diagnosis through pregnancy, as well as decisions regarding CDCA treatment during pregnancy...
July 17, 2023: Journal of Clinical Lipidology
Reika Masuda, Julien Wist, Samantha Lodge, Torben Kimhofer, Michael Hunter, Jennie Hui, John P Beilby, John R Burnett, Girish Dwivedi, Markus P Schlaich, Sze-How Bong, Ruey Leng Loo, Elaine Holmes, Jeremy K Nicholson, Bu B Yeap
BACKGROUND: Circulating lipids and lipoproteins mediate cardiovascular risk, however routine plasma lipid biochemistry provides limited information on pro-atherogenic remnant particles. OBJECTIVE: We analysed plasma lipoprotein subclasses including very low-density and intermediate-density lipoprotein (VLDL and IDL); and assessed their associations with health and cardiometabolic risk. METHODS: From 1,976 community-dwelling adults aged 45-67 years, 114/1071 women (10...
July 1, 2023: Journal of Clinical Lipidology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.